201
Views
3
CrossRef citations to date
0
Altmetric
Short Report

The use of methotrexate in conservative treatment of placenta accreta spectrum disorders

ORCID Icon, , , &
Pages 7514-7517 | Received 16 Nov 2020, Accepted 30 Jun 2021, Published online: 18 Jul 2021
 

Abstract

Aim of the study: This article reports on a series of patients with placenta accreta spectrum (PAS) disorder who were treated conservatively with Methotrexate (MTX) administration with or without embolization. We investigate whether there is a place for MTX in conservative treatment of PAS.

Methods: We present a single-center retrospective case series of five patients. In all patients, diagnosis was unexpected and not made prenatally.

Conclusion: The benefits should be weighed against the possible drug toxicity. Today high-quality evidence is lacking. PAS covers a broad spectrum of pathology, standardization in prenatal and postnatal diagnosis can help to compare evidence on treatment.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.